GU Cancers 2024 | Evaluating the role of radiotherapy in primary and metastatic RCC

Sophia Kamran, MD, Massachusetts General Hospital, Boston, MA, discusses the role of radiation in renal cell carcinoma (RCC). Findings from the Phase II FASTRACK II trial (NCT02613819) demonstrated the efficacy and safety of stereotactic ablative body radiotherapy (SABR) in patients with primary RCC. On the other hand, specifically targeting progressing sites with systemic therapy in patients with oligometastatic RCC have proven to be useful. Additional studies assessing radiotherapy with immune checkpoint inhibitors are underway. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.